Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Anna Nishihara, MD, Yuko Mishima, PhD, Tomoko Takayama, Yasuhito Terui, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hirofumi Yamauchi, MD, Norihito Inoue, MD, Naoko Tsuyama, MD PhD, Yuji Mishima, PhD, Kengo Takeuchi, MDPhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 2784.

https://doi.org/10.1182/blood.V130.Suppl_1.2784.2784

Published: 2017

Journal Articles

Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma

Hirofumi Yamauchi, MD, Yuko Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Nishihara, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 3116.

https://doi.org/10.1182/blood.V130.Suppl_1.3116.3116

Published: 2017

Journal Articles

The Prognosis of PR Patients after Induction Therapy Was Not Inferior to CR in ASCT-Eligible NDMM Patient.

Anna Takahashi, MD, Yuko Mishima, MD PhD, Norihito Inoue, MD, Yoshiharu Kusano, MD, Hirofumi Yamauchi, MD, Kyoko Ueda, MD, Noriko Nishimura, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 5682.

https://doi.org/10.1182/blood.V128.22.5682.5682

Published: 2016

Journal Articles

The Relapsed - Memorial Sloan - Kettering Cancer Center (R-MSKCC) Prognostic Score Is a Risk-Stratification Model for the Central Nervous System (CNS) Involvement at Relapse in Patients with Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab Era

Noriko Nishimura, MD PhD, Yasuhito Terui, MD PhD, Kengo Takeuchi, MD PhD, Naoko Tsuyama, MD, Anna Takahashi, MD, Norihito Inoue, MD, Hirofumi Yamauchi, MD, Yoshiharu Kusano, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 4221.

https://doi.org/10.1182/blood.V128.22.4221.4221

Published: 2016

Journal Articles

Azacitidin Is Effective in the Therapy Related Myelodysplastic Syndrome.

Hirofumi Yamauchi, MD, Masahiro Yokoyama, MD, Yuko Mishima, MD PhD, Noriko Nishimura, MD PhD, Kyoko Ueda, MD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Takahashi, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 5554.

https://doi.org/10.1182/blood.V128.22.5554.5554

Published: 2016

Journal Articles

Retrospective Analysis of NK/T Cell Lymphoma Prognostic Index (NKPI), EBV-DNA and Soluble IL-2 Receptor (sIL2R) for Extranodal NK/T-Cell Lymphoma, Nasal Type

Norihito Inoue, MD, Noriko Nishimura, MD PhD, Anna Takahashi, MD, Hirofumi Yamauchi, MD, Yoshiharu Kusano, MD, Kyoko Ueda, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 5360.

https://doi.org/10.1182/blood.V128.22.5360.5360

Published: 2016

NARROW

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma

The Prognosis of PR Patients after Induction Therapy Was Not Inferior to CR in ASCT-Eligible NDMM Patient.

The Relapsed - Memorial Sloan - Kettering Cancer Center (R-MSKCC) Prognostic Score Is a Risk-Stratification Model for the Central Nervous System (CNS) Involvement at Relapse in Patients with Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab Era

Azacitidin Is Effective in the Therapy Related Myelodysplastic Syndrome.

Retrospective Analysis of NK/T Cell Lymphoma Prognostic Index (NKPI), EBV-DNA and Soluble IL-2 Receptor (sIL2R) for Extranodal NK/T-Cell Lymphoma, Nasal Type

Email alerts

ASH Publications

American Society of Hematology

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma

The Prognosis of PR Patients after Induction Therapy Was Not Inferior to CR in ASCT-Eligible NDMM Patient.

The Relapsed - Memorial Sloan - Kettering Cancer Center (R-MSKCC) Prognostic Score Is a Risk-Stratification Model for the Central Nervous System (CNS) Involvement at Relapse in Patients with Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab Era

Azacitidin Is Effective in the Therapy Related Myelodysplastic Syndrome.

Retrospective Analysis of NK/T Cell Lymphoma Prognostic Index (NKPI), EBV-DNA and Soluble IL-2 Receptor (sIL2R) for Extranodal NK/T-Cell Lymphoma, Nasal Type

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only